← Browse by Condition
Medical Condition
systemic lupus erythematosus
Total Trials
20
Recruiting Now
20
Trial Phases
Phase 2, Phase 4, Phase 1
NCT00756769
Recruiting
Systemic Lupus Erythematosus in Gullah Health
Enrollment
750 pts
Location
United States
Sponsor
Medical University of South Ca...
NCT06659029
Recruiting
Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users
Enrollment
442 pts
Location
United States
Sponsor
AstraZeneca
NCT05440422 Phase 2
Recruiting
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
Enrollment
45 pts
Location
United States
Sponsor
National Institute of Arthriti...
NCT06361745
Recruiting
Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
Enrollment
10 pts
Location
China
Sponsor
PersonGen BioTherapeutics (Suz...
NCT06593041
Recruiting
ROLE of PLATELETS in the PATHOPHYSIOLOGY of SYSTEMIC LUPUS
Enrollment
450 pts
Location
France
Sponsor
University Hospital, Strasbour...
NCT07077486 Phase 4
Recruiting
Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease
Enrollment
100 pts
Location
China
Sponsor
Tongji Hospital
NCT07180537
Recruiting
Creating Health Course Study for People With Rheumatological Conditions
Enrollment
200 pts
Location
United States
Sponsor
Terry L. Wahls
NCT06984341 Phase 1
Recruiting
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)
Enrollment
162 pts
Location
United States
Sponsor
Genentech, Inc.
NCT06449794
Recruiting
Neuropsycatric Disorders Among Children With Systemic Lupus Erythematosus in Sohag University Hospital
Enrollment
50 pts
Location
Egypt
Sponsor
Sohag University
NCT06581562 Phase 1
Recruiting
Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
Enrollment
30 pts
Location
United States
Sponsor
IRIS Research and Development,...
NCT03816345 Phase 1
Recruiting
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Enrollment
300 pts
Location
United States, Canad...
Sponsor
National Cancer Institute (NCI...
NCT06794008 Phase 2
Recruiting
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
Enrollment
50 pts
Location
China
Sponsor
Peking University People's Hos...
NCT06121297 Phase 1, Phase 2
Recruiting
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Enrollment
28 pts
Location
United States, Canad...
Sponsor
Cabaletta Bio
NCT00001372
Recruiting
Study of Systemic Lupus Erythematosus
Enrollment
2,250 pts
Location
United States
Sponsor
National Institute of Arthriti...
NCT06365359
Recruiting
Systemic Lupus Erythematosus and Chlordecone Impregnation in Martinique
Enrollment
200 pts
Location
France
Sponsor
University Hospital Center of ...
NCT06570798 Phase 2
Recruiting
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
Enrollment
220 pts
Location
United States, Austr...
Sponsor
Amgen
NCT05559671 Phase 4
Recruiting
Safety of the Herpes Zoster Subunit Vaccine in Lupus
Enrollment
224 pts
Location
United States
Sponsor
NYU Langone Health
NCT06379646
Recruiting
An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
Enrollment
6 pts
Location
China
Sponsor
China Immunotech (Beijing) Bio...
NCT06691152 Phase 1
Recruiting
Efficacy and Safety of CD19 UCAR T Cells in Refractory Systemic Lupus Erythematosus
Enrollment
18 pts
Location
China
Sponsor
The Children's Hospital of Zhe...
NCT06934447 Phase 1
Recruiting
Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE
Enrollment
18 pts
Location
China
Sponsor
The Children's Hospital of Zhe...